Short interfering RNA vectors against VEGF-C and VEGF-A suppress lymphatic metastasis and lymphatic metastasis of mammary cancer model
Short interfering RNA vectors against VEGF-C and VEGF-A suppress lymphatic metastasis and lymphatic metastasis of mammary cancer model
批准号:
17591360
负责人:
SHIBATA Masa-aki
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Human breast cancers metastasize mainly to the lymph nodes, lungs, and intractable metastasis leads to death. VEGF-C expression has been shown to correlate with lymph node metastasis in a variety of human cancers. VEGF-A has also been reported to participate on hematogeneous metastasis. Syngeneic inoculated metastatic mammary cancers received direct intratumoral injection of psiRNA-SCR control vector, psiRNA-VEGF-C vector, psiRNA-VEGF-A or their combination once a week for 8 weeks. We applied electrogene transfer to the tumors after each injection. Tumor volume was significantly lower in the psiRNA-VEGF-A and the combination groups as compared to the control group. Both incidence and multiplicity of the lymph node metastasis were significantly less frequent in all therapeutic groups. While incidence of the lung metastasis in all groups was similar, the number of lung metastatic foci was significantly decreased in the combination group only. In addition, the numbers of dilated lymphatic vessels containing intaluminal tumor cells were significantly decreased in all therapeutic groups. Our data suggest that not only VEGF-C but also VEGF-A correlate to lymphatic metastasis, and the observed anti-metastasis activity of siRNA against VEGF-C and VEGF-A may be of high clinical significance in the treatment of metastatic breast cancer.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
転移性乳癌モデルを用いた実験的乳癌治療の試み-脈管を標的とした癌遺伝子治療-
使用转移性乳腺癌模型进行实验性乳腺癌治疗 - 针对血管的癌症基因治疗 -
DOI:
--
发表时间:
2007
期刊:
大阪医科大学雑誌 65・3
影响因子:
--
作者:
[Hiromichi Kawaida, Koji Kono, Hidemitsu Sugai, et al., 柴田雅朗]
通讯作者:
柴田雅朗
移転性乳癌モデルを用いた実験的癌治療の試み-脈管を標的とした癌遺伝子治療-
使用转移性乳腺癌模型进行实验性癌症治疗 - 针对血管的癌症基因治疗 -
DOI:
--
发表时间:
2007
期刊:
大阪医科大学雑誌 65・3
影响因子:
--
作者:
[Hiromichi Kawaida, Koji Kono, Hidemitsu Sugai, et al., 柴田雅朗, 柴田雅朗]
通讯作者:
柴田雅朗
Inhibition of lymph node metastasis of mammary cancer due to functional loss of lymphangiogenesis factors by siRNA and/or decoy vectors
-
批准号:19591520
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:SHIBATA Masa-aki
-
依托单位:
Combination cancer gene therapy in endostatin and suicide gene for metastatic murine mammary cancers
-
批准号:15591368
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.37万
-
财政年份:2003
-
负责人:SHIBATA Masa-aki
-
依托单位:
Gene therapy using apoptosis-inducer bax and suicide gene for chemically induced rat bladder cancer
-
批准号:12671567
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2000
-
负责人:SHIBATA Masa-aki
-
依托单位:
国内基金
海外基金
登录
查看更多内容
IGF2BP2通过m6A甲基化修饰调控VEGF-C转录促进头颈鳞癌淋巴管生成的机制研究
-
批准号:JCZRQNB202600634
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
免疫微环境重塑驱动MAPK–VEGF-C/VEGFR-3信号轴调控巨噬细胞促淋巴管再生的机制研究
-
批准号:JCZRQNB202600447
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
运动康复通过VEGF-C介导的淋巴管生成在骨腱界面损伤修复中的作用机制研究
-
批准号:2026JJ60250
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:童小鹏
-
依托单位:
VEGF-C 通过肝窦内皮细胞 FLT4/CXCL5 轴参
与非酒精性脂肪性肝纤维化的作用机制
-
批准号:TGY24H030017
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:洪薇
-
依托单位:
基于MAPK/ERK调控VEGF-C/VEGFR3 通路研究小檗碱联
合芒柄花黄素抗鼻咽癌转移分子机制
-
批准号:2024JJ9158
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:伍永慧
-
依托单位:
FABP4通过VEGF-C/VEGF-D/VEGFR-3信号轴调控非小细胞肺癌转移的作用及其机制
-
批准号:2023JJ30061
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:罗武
-
依托单位:
可视化微球示踪动态评价VEGF-C/PGF2α双重调控APP/PS1鼠颈部淋巴管功能的作用及机制研究
-
批准号:82370506
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:杜婷
-
依托单位:
SARG通过VEGF-C/VEGFR-3功能轴促进甲状腺癌淋巴道转移的机制研究
-
批准号:LBY23H200004
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:徐玲珑
-
依托单位:
VEGF-C和TNF-α在病毒感染的神经元与巨噬细胞互作中的功能研究
-
批准号:82302000
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:齐琳琳
-
依托单位:
基于VEGF-C/VEGFR-3信号通路探讨当归芍药散经脑膜淋巴管引流促进痴呆动物Aβ清除的机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:王奇
-
依托单位: